Alcobra ADHD Drug Fails Key Study Except When Patients Removed From Analysis

TEL AVIV (TheStreet) -- Treatment with an experimental formulation of vitamin B6 known as MDXafailed to improve the symptoms of attention-deficit hyperactivity disorder (ADHD) compared to placebo, according to phase III study results announced by the developer of the drug,aAlcobra , in a statement issued Monday. However, when Alcobra removed four placebo patients from the analysis because of "extreme" responses, the MDX benefit in the adult ADHD was positive and statistically significant, the co...